Systematic switch from Innovator Infliximab to Biosimilar Infliximab in Inflammatory Chronic Diseases in Daily Clinical Practice: The Experience of Cochin University Hospital, Paris, France

To investigate effectiveness of systematic switching treatment from innovator infliximab to biosimilar infliximab, and its associated factors.
Source: Seminars in Arthritis and Rheumatism - Category: Rheumatology Authors: Source Type: research